Form 990 for tax year 2024
Filed by DES MOINES ONCOLOGY RESEARCH ASSOCIATION.
Totals
- Total revenue
- $99,911
- Total expenses
- $148,207
- Contributions and grants received
- $0
- Grants paid
- $0
- Program service revenue
- $93,056
- Investment income
- $6,855
- Other revenue
- $0
- Total assets, end of year
- $873,472
- Total liabilities, end of year
- $0
- Net assets or fund balances, end of year
- $873,472
- Program services expenses (Part IX)
- $133,386
- Management and general expenses
- $14,821
- Fundraising expenses
- $0
- Program service expenses (Part III)
- $133,386
Program services were 90.0% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
Line items
Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.
Revenue
Part VIII, the statement of revenue.
-
2a · Program service revenue: INDUSTRY STUDIES
total $93,056 · related or exempt $93,056
-
3 · Investment income
total $6,855 · excluded $6,855
Functional expenses
Part IX, the statement of functional expenses.
-
7 · Other salaries and wages
total $128,009 · program services $115,208 · management and general $12,801
-
11g · Fees: other
total $1,000 · program services $900 · management and general $100
-
12 · Advertising and promotion
total $150 · program services $135 · management and general $15
-
24a · Other expenses: RESEARCH EXPENSES
total $19,048 · program services $17,143 · management and general $1,905
Balance sheet
Part X, book values.
-
1 · Cash, non-interest-bearing
beginning of year $657,688 · end of year $602,538
-
2 · Savings and temporary cash investments
beginning of year $264,079 · end of year $270,934
-
29 · Capital stock, trust principal or current funds
beginning of year $0 · end of year $0
-
30 · Paid-in or capital surplus, or land, building or equipment fund
beginning of year $0 · end of year $0
-
31 · Retained earnings, endowment or other funds
beginning of year $921,767 · end of year $873,472
Mission and programs · 2024
Mission
DES MOINES ONCOLOGY RESEARCH ASSOCIATION (DORA) IS ORGANIZED EXCLUSIVELY FOR SUPPORTING CANCER RESEARCH IN THE DES MOINES, IOWA AREA. DORA WILL RESPONSIBLY OVERSEE THE CONDUCT OF CANCER RESEARCH TRIALS AND SUPERVISE APPROPRIATE MANAGEMENT OF FUNDS FROM INDUSTRY SPONSORS OF RESEARCH TRIALS OR FROM PHILANTHROPIC DONATIONS TO SUPPORT LOCAL CANCER RESEARCH.
-
RESPONSIBLY OVERSEE THE CONDUCT OF CANCER RESEARCH TRIALS AND SUPERVISE APPROPRIATE MANAGEMENT OF FUNDS FROM INDUSTRY SPONSORS OF RESEARCH TRIALS OR FROM PHILANTHROPIC DONATIONS TO SUPPORT LOCAL CANCER RESEARCH.
Expenses $133,386 · Revenue $93,056
As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here.
Listed in Part VII
-
Robert Behrens MDROBERT BEHRENS MD
PRESIDENT
- Total calculated
- $0
- Hours/week
- 1
-
Joshua Lukenbill MDJOSHUA LUKENBILL MD
VICE PRESIDENT
- Total calculated
- $0
- Hours/week
- 1
-
Tara Graff MDTARA GRAFF MD
SECRETARY/TREASURER
- Total calculated
- $0
- Hours/week
- 1
-
Shannon BensonSHANNON BENSON
EXECUTIVE DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those.
Grants on this return
No itemized grants to organizations on this return.
Provenance
- Return type
- form_990
- Tax year
- 2024
- Filed
- 11 March 2025
- IRS schema version
- 2024v5.0
- Source object
- 202530819349300303
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.